According to Roch et al
Several components that participate in this process include carbohydrate-binding lectins, calnexin and calreticulin, binding immunoglobulin protein (BiP) and its cofactors, heat shock protein 70 (HSP70), and oxidative folding enzymes
In advanced cancer, caloric intake is inadequate to support metabolic demands,[4] which are often elevated due to an increased frequency of hypermetabolism.[5] In 2011, researchers in the field of cancer cachexia proposed a three-level distinct staging system consisting of pre-cachexia, cachexia, and a refractory stage.[6] In advanced nonsmall-cell lung or gastrointestinal cancers, patients classified as pre-cachectic and cachectic according to the proposed cancer cachexia staging system were clinically similar with respect to overall symptom burden, quality of life, tolerance of chemotherapy, and survival, whereas those in the refractory stage were unique and were noted to have deteriorating clinical outcomes.[7] Estimates of the prevalence of cancer cachexia vary widely due to variable diagnostic criteria used in the past.[8] In one study, more than one-half of 644 ambulatory cancer patients reported anorexia and weight loss exceeding 5% of premorbid weight.[9] Cancer patients are often referred for cachexia intervention treatments late in their disease trajectory-that is, at a point where attempts to reverse the weight loss process may be less beneficial.[10] In addition, healthcare professionals frequently under-recognize the prevalence of cancer cachexia,[11] and this may contribute to delayed treatment of weight loss, often until the refractory stage
CJC-1295 and Ipamorelin: Both are growth hormone-releasing peptides that can increase muscle mass and enhance fat loss by boosting growth hormone levels in the body
